Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Cystic Fibrosis: KOL Insight: Update Bulletin [May 2017]

Product Code:
April Date:
May 2017

This edition presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data from a Phase II study for anabasum (Resunab), an oral synthetic, oral endocannabinoid-mimetic drug for inflammation; Vertex Pharmaceuticals’s positive data from two Phase III (EVOLVE and EXPAND) studies of the tezacaftor (VX-661)/ivacaftor and observations on development of Galapagos/AbbVie’s novel corrector, GLPG2222 and the dosing of the first patient with CF Class III (F508del and a gating mutation like G551D).

Business Questions:

  • How do KOLs view the development of anabasum (Resunab) and how will the anti-inflammatory agent fit in the CF treatment paradigm?
  • What safety concerns do KOLs have with Resunab and what data is needed to convince these experts?
  • How do KOLs view the potential of Vertex Pharmaceuticals’s tezacaftor/ivacaftor and what conclusions do they draw from the available data?
  • What safety concerns do KOLs have for tezacaftor and how do these compare to lumacaftor?
  • Where do KOLs think tezacaftor/ivacaftor will fit into the current treatment paradigm for CF patients?
  • How do KOLs view Galapagos/AbbVie’s novel corrector and what challenges do they see with the development of GLPG2222?
  • Will GLPG2222 combinations be practice-changing and could Galapagos/AbbVie’s challenge Vertex’s dominance in the CF space?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved